

January 2, 2018



## Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference

SAN DIEGO and TORONTO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming Biotech Showcase™ 2018 Conference on Monday, January 8<sup>th</sup>, 2018 at 11:00 a.m. PST in San Francisco, CA.

### Conference Presentation Details:

**Date:** Monday, January 8, 2018  
**Time:** 11:00 a.m. PST  
**Location:** Track Yosemite - C (Ballroom Level)  
Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102  
**Webcast:** [https://event.webcasts.com/starthere.jsp?ei=1176654&tp\\_key=e58ab4bdea](https://event.webcasts.com/starthere.jsp?ei=1176654&tp_key=e58ab4bdea)

The audio webcast will be archived shortly after the live event and will be available through the Aptose website at [www.aptose.com](http://www.aptose.com).

The Company will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with Aptose, investors can [register](#) on the online system managed by the Company's US investor relations firm, [LifeSci Advisors, LLC](#), or make a request via e-mail at [Access@LifeSciAdvisors.com](mailto:Access@LifeSciAdvisors.com).

### About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

**Aptose Biosciences**  
Greg Chow, CFO

647-479-9828

[gchow@aptose.com](mailto:gchow@aptose.com)

LifeSci Advisors, LLC

Dan Ferry

Managing Director

617-535-7746

[Daniel@LifeSciAdvisors.com](mailto:Daniel@LifeSciAdvisors.com)



Source: Aptose Biosciences, Inc.